106 related articles for article (PubMed ID: 14999638)
1. Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study.
Palella FJ; Cole SR; Chmiel JS; Riddler SA; Visscher B; Dobs A; Williams C
Clin Infect Dis; 2004 Mar; 38(6):903-7. PubMed ID: 14999638
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.
Brown TT; Cole SR; Li X; Kingsley LA; Palella FJ; Riddler SA; Visscher BR; Margolick JB; Dobs AS
Arch Intern Med; 2005 May; 165(10):1179-84. PubMed ID: 15911733
[TBL] [Abstract][Full Text] [Related]
3. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy.
Brown TT; Chu H; Wang Z; Palella FJ; Kingsley L; Witt MD; Dobs AS
AIDS; 2007 Aug; 21(13):1731-8. PubMed ID: 17690571
[TBL] [Abstract][Full Text] [Related]
5. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients.
Palacios R; Santos J; García A; Castells E; González M; Ruiz J; Márquez M
HIV Med; 2006 Jan; 7(1):10-5. PubMed ID: 16313287
[TBL] [Abstract][Full Text] [Related]
6. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
[TBL] [Abstract][Full Text] [Related]
7. Body habitus in a cohort of HIV-seropositive and HIV-seronegative injection drug users.
Smit E; Semba RD; Pilibosian E; Vlahov D; Tun W; Purvis L; Tang AM
AIDS Patient Care STDS; 2005 Jan; 19(1):19-30. PubMed ID: 15665632
[TBL] [Abstract][Full Text] [Related]
8. Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons.
Boulassel MR; Morales R; Murphy T; Lalonde RG; Klein MB
J Med Virol; 2006 Sep; 78(9):1158-63. PubMed ID: 16847953
[TBL] [Abstract][Full Text] [Related]
9. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
10. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy.
Hartman K; Verweel G; de Groot R; Hartwig NG
Pediatr Infect Dis J; 2006 May; 25(5):427-31. PubMed ID: 16645507
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.
Maia BS; Engelson ES; Wang J; Kotler DP
Clin Nutr; 2005 Dec; 24(6):971-8. PubMed ID: 16095765
[TBL] [Abstract][Full Text] [Related]
13. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
14. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
15. Changes in leptin serum levels in HIV-infected children receiving highly active antiretroviral therapy.
Papaevangelou V; Papassotiriou I; Vounatsou M; Chrousos G; Theodoridou M
Scand J Clin Lab Invest; 2007; 67(3):291-6. PubMed ID: 17454843
[TBL] [Abstract][Full Text] [Related]
16. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
[TBL] [Abstract][Full Text] [Related]
17. Body shape and composition in HIV-infected women: an urban cohort.
Karmon SL; Moore RD; Dobs AS; Keruly J; Barnett S; Cofrancesco J
HIV Med; 2005 Jul; 6(4):245-52. PubMed ID: 16011529
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies.
Wohl DA
Top HIV Med; 2004; 12(3):89-93. PubMed ID: 15310940
[TBL] [Abstract][Full Text] [Related]
19. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
20. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
